• Inicio
  • Información sobre el cáncer
  • Linfomas no Hodgkin

Linfomas no Hodgkin

Índice de navegación

Bibliografía 

1 Swerdlow SH, Campo E, Pileri SA,et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375-90.
2 Solal-celigny P, Roy P, Colombat P, et al. Follicullar lymphoma international prognostic index. Blood 2004; 104: 1258-1265.
3 Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new pronostic index for folicular lymphoma developed by the international folicular lymphoma prognostic factor Project. J Clin Oncol 2009; 27: 4555-4562.
4 A predictive model for aggressive non-Hodgkin´s lymphoma. The International Malignant Lymphoma Prognostic factors project. N Engl J Med 1993; 329: 987.
5 Conconi A, Lobetti-Bodoni C, Montoto S, et al. Life expectancy of young adults with follicular lymphoma Ann Oncol. 2015 Nov;26(11):2317-22.
6 Mac Manus, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 1996; 14: 1282.
7 Wilder RB, Jones D, et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219.
8 Ardeshna KM, Smith P, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516.
9 Dreyling M, Ghielmini M, Rule S,et al.ESMO Guidelines Committee. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2016 Sep;27(suppl 5):v83-v90.
10 Lymphomas. Essential for clinicians. ESMO Press. Ghielmini M and Montoto S (eds). 2012.
11 Hiddemann W, Kneba M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma German Low-Grade Lymphoma Study Group. Blood 2005; 106:3725.
12 Van Oers MH, Klasa R, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295.
13 Pavanello F, Zucca E, Ghielmini M. Rituximab: 13 open questions after 20 years of clinical use. Cancer Treat Rev. 2017 Feb;53:38-46.
14 Provencio M, Cruz Mora MÁ, Gómez-Codina J, et al. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group Leuk Lymphoma. 2014 Jan;55(1):51-5.
15 Miller T, Dahlberg S, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-hodgkin´s lymphoma. N Engl J Med 1998; 339: 21.
16 Horning SJ, Weller E, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive Non-hodgkin´s lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004; 22:3032.
17 Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: A study the Groupe d´Etude des lymphomas de l´Adulte. J Clin Oncol 2007; 25 :787.
18 Pfreundschuh M, Trumper L, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera International Trial (MinT) Group . Lancet oncol 2006; 7:379.
19 Fisher R, Gaynor E, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-hodgkin´s lymphoma. N Engl J Med 1993; 328:1002.
20 Coiffier B, Lepage E et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002; 346: 235.
i Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease Discovery. Blood 2008; 112: 4384-99.
ii Arcaini L, Merli M, Passamonti F, Rizzi S, Ferretti V, et al. Validation of follicular lymphoma International prognostic index 2 (FLIPI2) score in an independent series of follicular lymphoma patients. Br J Haematol 2010, 149 (3): 455-7.
iii Federico M, Bellei M, Marcheselli L, Luminari S, et al. Follicular lymphoma International prognostic index 2: a new prognostic index for follicular lymphoma developed by the International follicular lymphoma prognostic factor Project. J Clin Oncol 2009; 27(27): 4555-62.
iv Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, Morabito F, Martelli M, Brusamolino E, Iannitto E, Zaja F, Cortelazzo S, Rigacci L, Devizzi L, Todeschini G, Santini G, Brugiatelli M, Federico M; Intergruppo Italiano Linfomi. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474-9.


12/12